Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases.

Halima El OmriRuba Y TahaAmna GamilFiryal IbrahimHisham Al SabahZeinab O MahmoudGianfranco PittariIbrahim Al HIjjiMohamed A Yassin

Published in: Clinical medicine insights. Blood disorders (2015)

Rituximab appears to be a safe and effective therapy for refractory and relapsing TTP. However, longer follow-up is recommended to assess relapse and detect possible long-term side effects of this therapy.

Keyphrases

multiple sclerosis
diffuse large b cell lymphoma
chronic lymphocytic leukemia
disease activity
hodgkin lymphoma
rheumatoid arthritis
stem cells
systemic lupus erythematosus
mesenchymal stem cells
bone marrow